



Tetrahedron: Asymmetry 14 (2003) 1691-1699

TETRAHEDRON: ASYMMETRY

Asymmetric synthesis of tetracyclic substructures of *Strychnos* indole alkaloids

Mercedes Amat,^{a,*} M.-Dolors Coll,^a Núria Llor,^a Carmen Escolano,^a Elies Molins,^b Carles Miravitlles^b and Joan Bosch^{a,*}

^aLaboratory of Organic Chemistry, Faculty of Pharmacy, University of Barcelona, 08028 Barcelona, Spain ^bInstitut de Ciència de Materials (CSIC), Campus UAB, 08193 Cerdanyola, Spain

Received 5 March 2003; accepted 10 March 2003

Abstract—The addition of the enolate of methyl 1-methyl-2-indoleacetate 1 and lithium 2-(lithiomethyl)indole-1-carboxylate 5 to pyridines and *N*-alkylpyridinium salts bearing a chiral auxiliary at the 3-position (tolylsulfinyl, acyl iron complexes, bornane-10,2-sultam), with subsequent acid cyclization of the resulting dihydropyridines, is investigated. © 2003 Elsevier Science Ltd. All rights reserved.

1. Introduction

An inspection of the polycyclic structure of *Strychnos* alkaloids,¹ for instance dihydroakuammicine, reveals that the stereogenic carbons common to two or more rings are configurationally correlated and that their relative and absolute configurations could be unambiguously attained starting from a suitably functionalized enantiopure 2-(1,4-dihydro-4-pyridylmethyl)indole **A** (Scheme 1). In fact, as a consequence of the bridge-



head character of carbons 3 and 15, the configuration at the dihydropyridine 4-carbon (C-15) would determine that of C-3 in the cyclization to the tetracyclic 1,5-methanoazocino[4,3-*b*]indole system **B** via a dihydropyridinium cation (bond formed C_3-C_7) and, afterwards, that of the quaternary C-7 center in the closure of the five-membered C-ring (bond formed C_6-C_7).^{2,3}

The development of the above synthetic strategy would require the generation of a chiral non-racemic 1,4dihydropyridine⁴ by diastereofacial-selective addition of an appropriate indole-containing nucleophile to an activated pyridine or pyridinium salt carrying a chiral auxiliary at the 3-position.^{5,6} Although the addition of indole-containing enolates to *N*-alkylpyridinium salts bearing an electron-withdrawing group at the 3-position has extensively been used in our laboratory as the initial step of a general and versatile method for the synthesis of indole alkaloids in the racemic series,⁷ there are few examples of the use of this methodology for the enantioselective synthesis of alkaloids.⁸

In this paper we report the results of applying the strategy depicted in Scheme 1 for the preparation of enantiopure tetracyclic ABDE substructures of *Strychnos* alkaloids using several chiral auxiliaries Y*.

2. Results and discussion

Scheme 1.

Initially, we planned to use a sulfinyl group as the chiral auxiliary. The electron-withdrawing nature of

0957-4166/03/ $\$ - see front matter $\$ 2003 Elsevier Science Ltd. All rights reserved. doi:10.1016/S0957-4166(03)00251-9

^{*} Corresponding authors. Tel.: +34 93 4024538; fax: +34 93 4024539; e-mail: amat@farmacia.far.ub.es; jbosch@farmacia.far.ub.es

this group should allow an efficient nucleophilic attack of a 2-indoleacetic ester enolate on the 4-position of the pyridine ring. Although the preparation of enantiopure (S)-3-(p-tolylsulfinyl)pyridine has been reported in the literature,⁹ to test the feasibility of the methodology we undertook a model study using the racemic tolylsulfinylpyridinium salt *rac*-2, which was easily accessible by methylation of the corresponding pyridine with methyl iodide (Scheme 2).



Scheme 2.

Interaction of the enolate of ester 1^{10} with pyridinium salt *rac*-2 at -30°C, followed by acid cyclization of the resulting 1,4-dihydropyridine gave the expected tetracyclic derivatives as a mixture of four diastereomers, *cis*- and *trans-rac*-3 and *cis*- and *trans-rac*-3' (*cis/trans* refers to the relative H₅-H₆ stereochemistry; 3 and 3' refers to the relative configuration of the bridgehead carbons with respect to the sulfur), which were separated by flash chromatography (32% overall yield). Tetracyclic *cis* sulfide *rac*-4 was also isolated in 12% yield.

Although the configuration of tetracycles rac-3 and rac-3' is not known, the H₅–H₆ cis/trans relationship for the pairs of isomers rac-3 (12% yield; 2:3 ratio) and rac-3' (20% yield; 3:2 ratio)¹¹ was deduced from the coupling constant of the doublet corresponding to H₆ (5 Hz in the *cis* isomers but 1.5 Hz in the *trans* isomers) in the ¹H NMR spectra and from the existence of *gauche* effects on C₄ (in the *cis* isomers) or C₁₂ (in the *trans* isomers) in the ¹³C NMR spectra.¹² The same criteria allowed the assignment of the relative *cis* H₅–H₆ configuration in *rac*-4. The above results indicated that the addition of the enolate to the pyridinium salt had taken place with a low facial stereoselectivity. For this reason, no further experiments were performed using enantiopure **2**.

We then turned our attention to chiral α,β -unsaturated acyl iron complexes, which have been developed by Davies and used in a variety of stereoselective conjugate additions,¹³ including the regio- and stereoselective addition of organolithium derivatives to nicotinoyl iron complexes to give the corresponding 4-alkyl-1,4dihydropyridines.¹⁴ However, when chiral non-racemic nicotinoyl iron complex (*R*)- 6^{15} was treated with 2-(lithiomethyl)indole **5** and the crude mixture was trapped with methyl chloroformate, only a nearly equimolecular mixture of C-2 diastereomeric 1,2-dihydropyridines 7 and 7' (57:43 ratio; absolute configuration at C-2 not determined) were obtained (Scheme 3). The chemical shift of H-2 ($\delta \sim 5.0$) and C-2 ($\delta \sim 53.3$) of the dihydropyridine ring were of diagnostic value.



 $Fe^* = (R)-[Fe(\eta^5-C_5H_5)(CO){PPh_2-(O-(-)-menthyl)}]$

Scheme 3.

Although the chemical yield of the above additionacylation sequence was excellent (76%) the regioselectivity of the process was not favorable to our synthetic interest, probably due to steric factors and the particular nature of the organolithium derivative **5**, which also bears a lithium carboxylate moiety.

As a further chiral auxiliary we selected (2R)-bornane-10,2-sultam,¹⁶ which has been extensively used by Oppolzer in a number of enantioselective transformations, including conjugate nucleophilic additions to *N*enoyl derivatives.

Acylation of this sultam with sodium hydride and nicotinoyl chloride hydrochloride gave the required nicotinoylsultam 8 in 92% yield. The addition of 2-(lithio-methyl)indole 5 to 8 followed by treatment of the resulting mixture with methyl chloroformate led to a mixture of the desired 1,4-dihydropyridine 9 (20%; a single stereoisomer) and 1,2-dihydropyridines 10 and 10' (20%; two stereoisomers in a 2:3 ratio, whose configuration at C-2 was not determined), which could be separated after repeated purification by column chromatography (Scheme 4).

Diagnostic NMR signals for the structural assignment of these dihydropyridines were those of the sp^3 methine moiety (H-4, δ 3.5 and C-4, δ 33.8 for the 1,4-isomer and H-2, δ 5.1 and C-2, δ 53.0 for the 1,2-isomers). The absolute configuration of the new stereogenic center in **9** was assigned taking into account the configuration of the cyclized product *trans*-**12b**.



Scheme 4.

Unfortunately, all attempts to cyclize *N*-acyl-1,4-dihydropyridine **9** under acidic conditions (AcOH–dioxane– H_2O^{3b} or HCl–benzene¹⁰) to a tetracyclic derivative resulted in failure, leading to complex unidentifiable mixtures.

These results prompted us to study a similar nucleophilic addition-cyclization sequence starting from indoleacetic ester 1 and N-alkylpyridinium salts 11a and 11b, which were prepared in 97 and 92% yield by alkylation of nicotinoyl sultam 8 with methyl iodide and benzyl chloride, respectively. Addition of the enolate derived from 1 to pyridinium salt 11a followed by treatment of the resulting crude mixture of dihydropyridines with HCl in benzene gave a mixture of the expected tetracycles 12a (10% yield) and the regioisomers 13a (28% yield), which could be separated after repeated column chromatography (Scheme 5). In some runs, minor amounts of polyunsaturated amine 14, formed by the opening of the 1,2-dihydropyridine ring promoted by the excess of base, were also isolated¹⁷ (Scheme 6).



Scheme 5.

Tetracycles *cis*-**12a** and *trans*-**12a** epimers at C-6¹⁸ possess the same absolute configuration at the bridgehead carbons, thus indicating that the nucleophilic addition to the 4-position of the pyridine ring had occurred with facial selectivity. The relative H_5-H_6 stereochemistry of **12** was deduced from the H_5-H_6 coupling constant



Scheme 6.

using the same criteria as in the above tetracycles *rac-3*. Formation of unnatural tetracycles **13a** (two epimers at C-1 of unknown absolute configuration at the bridge-head carbons¹⁸) can be accounted for by considering that, under acidic conditions, the 1,2-dihydropyridine initially formed by nucleophilic addition of the enolate to the 6-position of the pyridinium ring is protonated, and that the resulting 1,2-dihydropyridinium cation undergoes intramolecular conjugate addition by the indole ring. Probably, the bulkiness of the chiral auxiliary, which hinders the approach of the nucleophile to the adjacent 4-position of the pyridine ring, is responsible for this undesirable regioselectivity.

The use of benzylpyridinium salt **11b** in the above two-step sequence led to a similar result and allowed us to isolate (27% overall yield) the expected tetracycles 12b (two epimers at C-6, cis-12b and trans-12b), again with the same absolute configuration at the bridgehead carbons, and two regioisomeric tetracycles 13b and 13'b, both of them with a H_1-H_2 trans relative stereochemistry ($J \sim 1.5$ Hz) and, consequently, with different absolute configuration (not determined) at the bridgehead carbons. The absolute configuration at the bridgehead carbons in tetracycles 12 was unambiguously established from the X-ray crystallographic analysis of trans-12b.19 On the other hand, the structural assignment of tetracycles 13 was effected from the ¹³C NMR chemical shift values of the bridgehead methine carbons ($\delta \sim 23$ and 56 for 13 versus $\delta \sim 29$ and 48 for tetracycles 12).

In conclusion, the results presented here, in conjunction with those previously reported from a chiral oxazolinylpyridine,⁶ show that the strategy for the synthesis of enantiopure tetracyclic precursors of *Strychnos* alkaloids based on the enantioselective generation of 1,4dihydropyridines by nucleophilic addition of a 2-indolylmethyl moiety to pyridines or pyridinium salts bearing a chiral auxiliary at the 3-position, and their subsequent acid cyclization, suffers from two main drawbacks that seriously limit its application: the low facial stereoselectivity, as a consequence of an inefficient coordination of the nucleophile with the chiral auxiliary, and/or the low regioselectivity due to the bulkiness of the chiral auxiliary.

3. Experimental

3.1. General

Melting points were determined in a capillary tube and are uncorrected. Unless otherwise indicated, NMR spectra were recorded at 200 or 300 MHz (1H) and 50.3 or 75 MHz (¹³C) and chemical shifts are reported in δ values downfield from TMS. Only noteworthy IR absorptions are listed. Thin-layer chromatography was done on SiO₂ (silica gel 60 F_{254}), and the spots were located with aqueous potassium permanganate solution or with iodoplatinate reagent. Column chromatography was carried out using the flash chromatography technique. All non-aqueous reactions were performed under an inert atmosphere. Solvents for chromatography were distilled at atmospheric pressure prior to use and dried following standard procedures. Drying of the organic extracts during the workup of reactions was performed over anhydrous Na₂SO₄ or MgSO₄. Evaporation of solvents was accomplished with a rotatory evaporator. Microanalyses and HRMS were performed by Centre D'Investigació i Desenvolupament (CSIC), Barcelona.

3.2. Preparation of 1-methyl-3-(*p*-tolylsulfinyl)-pyridinium iodide *rac*-2

A solution of methyl iodide (0.6 mL, 0.66 mmol) in benzene (1.2 mL) was slowly added to a cooled (0°C) solution of 3-(*p*-tolylsulfinyl)pyridine^{9b} (700 mg, 3.22 mmol) in acetone (1 mL). The mixture was stirred for 12 h and the solid was filtered and dried to give *rac*-**2** (930 mg, 80%). *rac*-**2**: IR (NaCl) 1053 cm⁻¹; ¹H NMR (CDCl₃, 200 MHz) δ 2.34 (s, 3H, CH₃Ar), 4.40 (s, 3H, N-CH₃), 7.42 and 7.76 (2d, *J*=8.1, 4H, ArH), 8.21 (dd, *J*=8.2, 6.0 Hz, 1H, H-5), 8.75 (dd, *J*=8.2, 1.2 Hz, 1H, H-4), 9.07 (d, *J*=6.0 Hz, 1H, H-6), 9.39 (s, 1H, H-2); ¹³C NMR (DMSO, 50.3 MHz) δ 21.2 (CH₃Ar), 48.9 (N-CH₃), 125.6 (C-*o*), 128.5 (C-5), 130.7 (C-*m*), 140.4 (C-*p*), 140.8 (C-4), 142.2 (C-6), 143.1 (C-*i*), 147.1 (C-3), 147.8 (C-2).

3.3. General procedure for the addition of methyl 1methyl-2-indoleacetate 1 to the pyridinium salts *rac*-2 and 11

LDA (1.5 M in THF, 1.5 mmol) was added to a cooled (-78° C) solution of ester 1 (1 mmol) in THF (25 mL). The mixture was stirred for 1 h at this temperature, and the pyridium salt (1 mmol) was added portionwise. Then, the mixture was warmed to -30° C and stirred for 2 h. The suspension was acidified to pH 3–4 with a solution of HCl in benzene. The temperature of the mixture was raised to -10° C and stirring was continued for 90 min. The mixture was poured into saturated aqueous Na₂CO₃, and the aqueous phase was extracted with EtOAc. The combined organic phases were dried

and evaporated to give a residue, which was column chromatographed.

3.4. Reaction of methyl 1-methyl-2-indoleacetate 1 with 1-methyl-3-(*p*-tolylsufinyl)pyridinium iodide *rac*-2

Following the above general procedure, from ester 1 (285 mg, 1.4 mmol) and pyridinium iodide rac-2 (500 mg, 1.4 mmol) a residue was obtained. Purification by column chromatography (EtOAc 100%, increasing polarity with EtOH) gave four fractions. Further purification of the first fraction by column chromatography (3:7 EtOAc/hexane) gave rac-4 (73 mg, 12%) and traces of 1. The second fraction was a mixture of cis-rac-3 and *trans-rac-3*, which were separated after an additional flash chromatography (95:5 Et₂O/EtOH) to give (12% overall yield) pure cis-rac-3 (27 mg) and transrac-3 (45 mg). The third and fourth fractions gave cis-rac-3' (71 mg) and trans-rac-3' (48 mg), respectively (20% overall yield). rac-4: mp 154-156°C (EtOAc); IR (NaCl) 1719, 1610, 1201, 1166, 745 cm⁻¹; ¹H NMR $(CDCl_3, 200 \text{ MHz}) \delta 2.03 \text{ (dt, } J=12.1, 2.7 \text{ Hz}, 1\text{H},$ H-12), 2.21 (dt, J = 12.1, 3.5 Hz, 1H, H-12), 2.31 (s, 3H, CH₃Ar), 3.03 (s, 3H, N₂-CH₃), 3.11 (br s, 1H, H-5), 3.55 (s, 3H, N₇-CH₃), 3.88 (s, 3H, OCH₃), 4.10 (d, J=5.1 Hz, 1H, H-6), 4.48 (br s, 1H, H-1), 6.53 (s, 1H, H-3), 7.10–7.30 (m, 7H, ArH), 7.60 (d, J=7.0 Hz, 1H, H-11); ¹³C NMR (CDCl₃, 50.3 MHz) δ 20.9 (CH₃Ar), 31.0 (N₇-CH₃), 31.6 (C-12), 34.4 (C-5), 41.2 (N₂-CH₃), 47.6 (C-6), 48.8 (C-1), 52.4 (OCH₃), 91.9 (C-4), 109.1 (C-8), 111.1 (C-11b), 118.1 (C-11), 119.6 (C-10), 121.5 (C-9), 126.2 (C-11a), 126.3 (C-o), 129.5 (C-m), 133.4 (C-p), 136.9 (C-i), 137.4 (C-7a), 146.0 (C-3), 172.8 (CO); m/z 447 (M⁺+29, 7), 419 (M⁺+1, 62), 418 (M⁺, 100), 241 (14), 240 (79), 216 (16). Anal. calcd for C₂₅H₂₆N₂O₂S·1/2 C₄H₈O₂: C, 70.10; H, 6.54; N, 6.06; S, 6.93. Found: C, 69.95; H, 6.43; N, 6.35; S, 6.67. cis-rac-3: mp 156°C (acetone); IR (NaCl) 1741, 1618, 1470, 1167, 1029, 747 cm⁻¹; ¹H NMR (CDCl₃, 200 MHz) δ 1.79 (dt, J=12.1, 3.3 Hz, 1H, H-12), 1.89 (dt, J=12.1, 2.7 Hz, 1H, H-12), 2.41 (s, 3H, CH₃Ar), 2.74 (m, 1H, H-5), 3.11 (s, 3H, N₂-CH₃), 3.56 (s, 3H, N₇-CH₃), 3.92 $(s, 3H, OCH_3), 4.10 (d, J = 5.2 Hz, 1H, H-6), 4.48 (br s, J)$ 1H, H-1), 6.87 (s, 1H, H-3), 7.10–7.30 (m, 5H, ArH), 7.57 (d, J=8.1 Hz, 2H, o-), 7.63 (d, J=7.0 Hz, 1H, H-11); ¹³C NMR (CDCl₃, 50.3 MHz) δ 21.4 (CH₃Ar), 29.9 (C-12), 30.0 (C-5), 30.9 (N₇-CH₃), 41.5 (N₂-CH₃), 48.5 (C-6), 48.9 (C-1), 52.7 (OCH₃), 103.4 (C-4), 109.1 (C-8), 111.4 (C-11b), 118.1 (C-11), 119.7 (C-10), 121.7 (C-9), 125.9 (C-11a, masked), 125.9 (C-o), 129.8 (C-m), 132.5 (C-6a), 136.3 (C-3), 137.3 (C-7a), 141.6 (C-3), 142.5 (C-i), 172.4 (CO); m/z 475 (M⁺+41, 2), 463 (M⁺+29, 11), 435 (M⁺+1, 73), 419 (30), 418 (57), 387 (22), 386 (61), 297 (25), 296 (100), 240 (52), 239 (10). Anal. calcd for C25H26N2O3S·1/2 H2O: C, 67.69; H, 6.13; N, 6.31; S, 7.22. Found: C, 67.49; H, 6.10; N, 6.17; S, 6.81. trans-rac-3: mp 154°C (EtOH); IR (NaCl) 1731, 1613, 1470, 1200, 1030, 752 cm⁻¹; ¹H NMR $(CDCl_3, 200 \text{ MHz}) \delta 1.67 \text{ (dt, } J=12.7, 3.1 \text{ Hz}, 1\text{H},$ H-12), 2.14 (dt, J = 12.7, 2.5 Hz, 1H, H-12), 2.43 (s, 3H, CH₃Ar), 3.01 (br s, 1H, H-5), 3.12 (s, 3H, N₂-CH₃), 3.61 (s, 3H, N₇-CH₃), 3.64 (s, 3H, OCH₃), 4.48 (br s, 1H, H-1), 4.58 (d, J=1.8 Hz, 1H, H-6), 6.77 (s, 1H,

1695

H-3), 7.10–7.25 (m, 3H, ArH), 7.33 (d, J=8 Hz, 2H, *m*-), 7.54 (d, J=8.1 Hz, 2H, o-), 7.60 (d, J=7.5 Hz, 1H, H-11); ¹³C NMR (CDCl₃, 75 MHz) δ 21.3 (CH₃Ar), 26.4 (C-12), 29.2 (C-5), 30.1 (N₇-CH₃), 41.8 (N₂-CH₃), 47.5 (C-6), 49.0 (C-1), 52.1 (OCH₃), 107.2 (C-4), 109.2 (C-8), 109.2 (C-11b), 118.1 (C-11), 119.5 (C-10), 121.5 (C-9), 124.9 (C-o), 125.4 (C-11a), 129.5 (C-m), 133.5 (C-6a), 137.0 (C-7a), 138.7 (C-p), 141.5 (C-i), 144.3 (C-3), 171.4 (CO); m/z 475 (M⁺+41, 1), 463 $(M^++29, 5), 435 (M^++1, 53), 434 (M^+, 24), 419 (55), 418$ (100), 296 (25), 240 (72), 216 (33). Anal. calcd for C₂₅H₂₆N₂O₃S: C, 69.10; H, 6.03; N, 6.44; S, 7.38. Found: C, 68.91; H, 5.90; N, 6.32; S, 7.11. cis-rac-3': mp 202-204°C (acetone); IR (NaCl) 1733, 1607, 1471, 1036, 748 cm⁻¹; ¹H NMR (CDCl₃, 200 MHz) δ 1.70 (dt, J=12.3, 3.5 Hz, 1H, H-12), 1.92 (dt, J=12.3, 2.5)Hz, 1H, H-12), 2.38 (s, 3H, CH₃Ar), 3.10 (s, 3H, N₂-CH₃), 3.24 (m, 1H, H-5), 3.55 (s, 3H, N₇-CH₃), 3.93 (s, 3H, OCH₃), 4.14 (d, J = 5.5 Hz, 1H, H-6), 4.45 (br s, 1H, H-1), 6.69 (s, 1H, H-3), 7.10-7.48 (m, 7H, ArH), 7.60 (d, J=7.1 Hz, 1H, H-11); ¹³C NMR (CDCl₃, 50.3 MHz) δ 21.1 (CH₃Ar), 29.1 (C-5), 29.6 (C-12), 30.8 (N_7-CH_3) , 41.4 (N_2-CH_3) , 48.1 (C-6), 49.3 (C-1), 52.5 (OCH₃), 106.4 (C-4), 109.0 (C-8), 111.3 (C-11b), 117.5 (C-11), 119.5 (C-10), 121.5 (C-9), 124.8 (C-o), 125.4 (C-11a), 129.1 (C-m), 133.2 (C-6a), 137.1 (C-7a), 139.3 (C-p), 140.8 (C-i), 143.4 (C-3), 171.8 (CO); m/z 475 $(M^++41, 2), 463 (M^++29, 9), 435 (M^++1, 59), 418 (27),$ 387 (22), 386 (60), 297 (21), 296 (21), 296 (100), 240 (15). Anal. calcd for $C_{25}H_{26}N_2O_3S \cdot 1/2C_3H_6O$: C, 68.65; H, 6.30; N, 6.04; S, 6.91. Found: C, 68.40; H, 5.96; N, 6.31; S, 7.14. trans-rac-3': mp 206°C (acetone); IR (NaCl) 1731, 1609, 1470, 1035 cm⁻¹; ¹H NMR (CDCl₃, 200 MHz) δ 1.88 (dt, J=12.5, 3.3 Hz, 1H, H-12), 2.21 (dt, J=12.5, 2.2 Hz, 1H, H-12), 2.43 (s, 3H, CH₃Ar),2.51 (d, J=1.9 Hz, 1H, H-6), 3.13 (s, 3H, N₂-CH₃), 3.15 (s, 3H, N₇-CH₃), 3.60 (s, 3H, OCH₃), 3.68 (br s, 1H, H-5), 4.53 (br s, 1H, H-1), 6.78 (s, 1H, H-3), 7.10-7.30 (m, 5H, ArH), 7.50 (d, J=8.1 Hz, 2H, o-), 7.61 (d, J = 7.0 Hz, 1H, H-11); ¹³C NMR (CDCl₃, 50.3 MHz) δ 21.3 (CH₃Ar), 25.2 (C-5), 26.7 (C-12), 29.1 (N_7-CH_3) , 41.8 (N_2-CH_3) , 44.1 (C-6), 49.0 (C-1), 52.1 (OCH₃), 107.0 (C-4), 109.0 (C-8), 109.4 (C-11b), 118.2 (C-11), 119.5 (C-10), 121.5 (C-9), 124.9 (C-o), 125.5 (C-11a), 129.3 (C-m), 133.0 (C-6a), 137.2 (C-7a), 139.9 (C-p), 140.8 (C-i), 143.5 (C-3), 171.1 (CO); m/z 475 (M⁺+41, 2), 463 (M⁺+29, 10), 435 (M⁺+1, 100), 434 (M, 36), 418 (24), 359 (15), 296 (24). Anal. calcd for C₂₅H₂₆N₂O₃S: C, 69.10; H, 6.03; N, 6.44; S, 7.38. Found: C, 68.99; H, 6.01; N, 6.35; S, 7.29.

3.5. Reaction of lithium 2-(lithiomethyl)indole-1-carboxylate 5 with (R)-[Fe(η^5 -C₅H₅)(CO){PPh₂(O-(-) menthyl})(nicotinoyl)] (R)-6

Butyllithium (1.6 M in hexanes, 3.2 mL, 5.1 mmol) was added to a cooled (-78° C) solution of 2-methylindole (0.65 g, 5.0 mmol) in THF (9 mL). After stirring for 5 min, a stream of dry CO₂ was bubbled into the solution for 5 min to give a yellowish solution, which was stirred for 20 min at -78° C. Then, excess of CO₂ was removed at reduced pressure at 0°C to give a residue, which was dissolved in THF (10 mL). The solution was cooled at

-78°C and tert-butyllithium (1.7 M in pentane, 3 mL, 5.1 mmol) was added. The temperature was raised to -20° C and stirring was continued for 45 min. The mixture containing 2-(lithiomethyl)indole 5 was cooled at -78°C and was transferred via canula to a cooled (-78°C) solution of pyridine (R)-6¹⁵ (0.59 g, 1.0 mmol) in THF (85 mL). After 3 h, methyl chloroformate (0.5 mL, 6.4 mmol) was added, and the mixture was stirred at -78°C for 30 min and at room temperature for additional 30 min. The organic solvent was removed at reduced pressure to give a residue, which was dissolved in CH₂Cl₂, washed with brine, and dried. Removal of the solvent followed by column chromatography (1:1 Et₂O/hexane) afforded starting 2-methylindole (0.3 g), methyl 2-indoleacetate (0.13 g) and a 43:57 mixture of the epimers, 7 and 7', respectively (0.60 g, 76%). 7: $[\alpha]_D^{22}$ +213 (c 0.2, EtOH); IR (NaCl) 2955, 1914, 1721, 1438 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz) δ 0.07 (s, 3H, CH₃), 0.68 (d, J = 6.9 Hz, 3H, CH₃), 0.86 (d, J = 6.6 Hz, 3H, CH₃), 0.70-2.00 (m, 9H, menthyl), 2.85 (m, 1H, Ind-CH₂), 3.05 (m, 1H, Ind-CH₂), 3.70–3.90 (m, 4H, CH₃O, POCH), 4.26 (br s, 5H, C₅H₅), 5.00 (br s, 1H, H-2), 5.41 (br s, 1H, H-3), 6.18 (br s, 1H, H-4), 6.27 (s, 1H, H-3 ind), 6.99–7.52 (m, 13H, H-6, 12H, ArH), 8.11 (m, 2H, ArH), 8.30 (br s, 1H, NH); ¹H NMR (DMSO-*d*₆, 300 MHz, 60°C) δ 0.22 (d, J=6.7 Hz, 3H, CH₃), 0.67 $(d, J = 6.9 \text{ Hz}, 3H, CH_3), 0.78 (d, J = 6.3 \text{ Hz}, 3H, CH_3),$ 0.66-2.00 (m, 9H, menthyl), 2.83 (dd, J=14.0, 5.2 Hz, 1H, Ind-CH₂), 2.99 (dd, J = 14.0, 7.2 Hz, 1H, Ind-CH₂), 3.69 (br s, 4H, CH₃O, POCH), 4.27 (m, 5H, C₅H₅), 5.03 (m, 1H, H-2), 5.42 (dd, J=9.7, 5.5 Hz, 1H, H-3), 6.10 (s, 1H, H-3 ind), 6.13 (br s, 1H, H-4), 6.85-7.56 (m, 13H, H-6, 12H, ArH), 7.93 (m, 2H, ArH), 10.75 (br s, 1H, NH); ¹³C NMR (CDCl₃, 75 MHz) δ 15.3 (C-10'), 21.5 (C-9'), 22.3 (C-7'), 22.9 (C-5'), 25.0 (C-8'), 31.6 (C-1'), 33.4 (Ind-CH₂), 34.1 (C-6'), 43.7 (C-2'), 49.7 (d, J_{PC}=4.6 Hz, C-4'), 53.4 (C-2), 53.8 (CH₃O), 77.0 (C-3'), 85.6 (C₅H₅), 101.9 (C-3 ind), 110.6 (C-7 ind), 119.6 (C-4 ind), 119.8 (C-5 ind, C-3), 121.2 (C-6 ind), 123.1 (C-4), 127.5 (d, J_{PC} =11.0 Hz, C-m), 127.6 (d, J_{PC} =9.8 Hz, C-m), 128.5 (C-3a ind), 129.9 (C-p), 131.5 (C-6), 131.9 (d, $J_{PC} = 10.0$ Hz, C-o), 134.4 (C-2 ind), 136.1 (C-7a ind), 165.4 (CO), 221.8 (d, $J_{PC} = 36.5$ Hz, CO). 7': $[\alpha]_{D}^{22}$ -16 (c 0.2, EtOH); IR (NaCl) 2955, 1914, 1725, 1437 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz) δ 0.20 (d, J=6.9 Hz, 3H, CH₃), 0.72 (d, J = 6.9 Hz, 3H, CH₃), 0.87 (d, J = 6.6 Hz, 3H, CH₃), 0.78–2.08 (m, 9H, menthyl), 2.99 (br s, 1H, Ind-CH₂), 3.30 (br s, 1H, Ind-CH₂), 3.80 and 3.87 (2s, 3H, CH₃O), 3.83 (s, 1H, POCH), 4.51 (m, 5H, C_5H_5), 5.00 (br s, 1H, H-2), 5.41 (dd, J=9.8, 5.6 Hz, 1H, H-3), 6.20 (br s, 1H, H-4), 6.33 (s, 1H, H-3 ind), 7.01–7.60 (m, 12H, ArH), 7.90 (br s, 1H, H-6), 8.10 (m, 2H, ArH), 8.33 (br s, 1H, NH); ¹H NMR (DMSO-d₆, 300 MHz, 70°C) δ 0.29 (d, J=6.9 Hz, 3H, CH₃), 0.70 $(d, J=7.1 \text{ Hz}, 3\text{H}, \text{CH}_3), 0.80 (d, J=6.3 \text{ Hz}, 3\text{H}, \text{CH}_3),$ 0.70-2.00 (m, 9H, menthyl), 2.90 (m, 1H, Ind-CH₂), 3.47 (br s, 1H, Ind-CH₂), 3.74 and 3.81 (2s, 3H, CH₃O), 3.70-3.90 (s masked, 1H, POCH), 4.45 (s, 5H, C₅H₅), 5.04 (m, 1H, H-2), 5.49 (dd, J=9.5, 5.2 Hz, 1H, H-3), 6.15 (br s, 1H, H-4), 6.19 (s, 1H, H-3 ind), 6.80-8.00 (m, 15H, H-6, ArH), 10.75 (br s, 1H, NH); ¹³C NMR (CDCl₃, 75 MHz) & 15.3 (C-10'), 21.5 (C-9'), 22.2 (C-7'), 23.0 (C-5'), 25.0 (C-8'), 31.6 (C-1'), 34.0 (IndCH₂), 34.1 (C-6'), 43.7 (C-2'), 49.7 (d, J_{PC} =4.8 Hz, C-4'), 53.3 (C-2), 53.4 and 53.9 (CH₃O), 77.0 (C-3'), 85.8 (C₅H₅), 101.8 (C-3 ind), 110.5 (C-7 ind), 119.5 (C-4 ind), 119.8 (C-5 ind), 121.2 (C-6 ind), 121.8 (C-3), 123.5 (C-4), 127.5 (d, J_{PC} =10.2 Hz, C-*m*), 127.6 (d, J_{PC} =10.2 Hz, C-*m*), 127.6 (d, J_{PC} =10.2 Hz, C-*m*), 131.8 (d, J_{PC} =9.1 Hz, C-*o*), 131.9 (d, J_{PC} =9.6 Hz, C-*o*), 132.0 (C-6), 134.3 (C-2 ind), 136.2 (C-7a ind).

3.6. Preparation of (2*R*)-*N*-nicotinoylbornane-10,2-sultam 8

A solution of nicotinic acid (3.43 g, 27.9 mmol) and thionyl chloride (18 mL) was heated at reflux for 90 min. Removal of the excess of thionyl chloride provided the nicotinoyl chloride hydrochloride as a white solid, which was used without further purification. A solution of (2R)-bornane-10,2-sultam (4.0 g, 18.6 mmol) in toluene (80 mL) was slowly added to a suspension of sodium hydride (55%, 2.4 g, 55.8 mmol) in toluene (40 mL) and the mixture was stirred at rt for 30 min. Then, a suspension of nicotinoyl chloride hydrochloride (3.8 g, 33.48 mmol) in toluene (80 mL) was slowly added and the mixture was stirred for 2 h 30 min. The reaction was quenched with saturated aqueous NH4Cl and the phases were separated. The aqueous phase was extracted with EtOAc and the combined organic extracts were dried and concentrated to furnish 8 (5.48 g, 92%). 8: $[\alpha]_{D}^{22}$ -212 (c 1, EtOH); mp 136°C (acetone); IR (NaCl) 1673, 1336, 1302 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz) δ 1.02 (s, 3H, CH₃), 1.32 (s, 3H, CH₃), 1.40–2.15 (m, 7H, bornane), 3.43 and 3.55 (2d, J=13.7Hz, 2H, CH₂SO₂), 4.16 (m, 1H, CHNCO), 7.37 (dd, J=7.9, 4.9 Hz, 1H, H-5), 8.06 (dt, J=7.9, 1.8 Hz, 1H, H-4), 8.76 (dd, J=4.9, 1.8 Hz, 1H, H-6), 8.92 (s, 1H, H-2); ¹³C NMR (CDCl₃, 75 MHz) δ 19.9 (C-7), 21.0 (C-8), 26.3 (C-5), 32.7 (C-6), 38.0 (C-3), 44.7 (C-4), 47.6 (C-7), 48.1 (C-1), 53.1 (C-10), 65.5 (C-2), 122.6 (C-5 pyr), 129.6 (C-3 pyr), 136.5 (C-4 pyr), 149.9 (C-6 pyr), 152.8 (C-2 pyr), 167.7 (CO). Anal. calcd for $C_{16}H_{20}N_2O_3S$: C, 59.98; H, 6.29; N, 8.74; S, 10.00. Found: C, 59.99; H, 6.38; N, 8.77; S, 10.11.

3.7. Reaction of lithium 2-(lithiomethyl)indole-1-carboxylate 5 with (2R)-N-nicotinoylbornane-10,2-sultam 8

A suspension of 2-(lithiomethyl)indole 5, prepared as described above from 2-methylindole (615 mg, 4.7 mmol), was transferred via canula at -78°C to a cooled $(-78^{\circ}C)$ solution of sultam 8 (500 mg, 1.6 mmol) in THF (28 mL). After 3 h of stirring, methyl chloroformate (0.6 mL, 7.8 mmol) was added, and the mixture was stirred at -30°C for 30 min and at room temperature for additional 30 min. The mixture was poured into saturated aqueous Na₂CO₃, and the aqueous phase was extracted with EtOAc. The combined organic extracts were dried and concentrated to give a residue, which was chromatographed (gradient from 7:3 hexane/ EtOAc to EtOAc). The first fraction provided unreacted 5. The second fraction gave 254 mg of a mixture of 9 and 10, which were separated after an additional column chromatography (7:3 Et₂O/hexane) furnishing

pure 10 (65 mg, 8%) and 9 (99 mg). The third fraction gave 350 mf of 9 and 10', which were separated by column chromatography (4:6 EtOAc/hexane) furnishing pure 9 (63 mg, 20% overall yield) and 10' (95 mg, 12%). 9: IR (NaCl) 2960, 1738, 1675, 1442, 1331, 1268, 1239, 749 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz) δ 0.98 (s, 3H, CH₃), 1.23 (s, 3H, CH₃), 1.30-2.10 (m, 7H, sultam), 3.00 (dd, J = 15.0, 8.2 Hz, 1H, Ind-CH₂), 3.23 (d, J = 15.0 Hz, 1H, Ind-CH₂), 3.40 and 3.49 (2d, J = 13.7Hz, 2H, CH₂SO₂), 3.42–3.50 (m, 1H, H-4), 3.77 (s, 3H, CH₃O), 4.14 (dd, J=7.2, 4.1 Hz, 1H, CHNSO₂), 5.10 (br s, 1H, H-5), 6.23 (s, 1H, H-3 ind), 6.80 (br s, 1H, H-6), 7.03–7.28 (m, 3H, ArH), 7.52 (d, J=7.4 Hz, 1H, H-4 ind), 7.75 (br s, 1H, H-2), 8.45 (br s, 1H, NH); ¹³C NMR (CDCl₃, 75 MHz) δ 19.8 (C-10), 21.0 (C-8), 26.6 (C-5), 32.9 (C-6), 33.8 (C-4 pyr), 36.5 (Ind-CH₂), 37.9 (C-3), 45.0 (C-4), 47.7 (C-7), 47.9 (C-1), 53.2 (C-10), 54.1 (CH₃O), 65.3 (C-2), 101.3 (C-3 ind), 110.4 (C-7 ind), 111.8 (C-5 pyr), 113.0 (C-3 pyr), 119.3 (C-4 ind), 119.7 (C-5 ind), 120.8 (C-6 ind), 122.0 (C-6 pyr), 128.6 (C-3a ind), 136.0 (C-2 ind), 136.2 (C-7a ind), 136.7 (C-2 pyr), 151.2 (CO₂CH₃), 169.4 (CONSO₂), *m*/*z* 509 (M⁺), 380 (22), 379 (100), 106 (21), 93 (19); HRMS calcd for C₂₇H₃₀N₃O₅S 508.1906, found 508.1872. 10: ¹H NMR (CDCl₃, 200 MHz, most relevant signals) δ 1.04 (s, 3H, CH₃), 1.30 (s, 3H, CH₃), 3.10 (m, 2H, Ind-CH₂), 3.79 (s, 3H, CH₃O), 5.10 (m, 1H, H-2), 5.75 (m, 1H, H-3), 6.30 (s, 1H, H-3 ind), 6.50 (d, J=9.3 Hz, H-4), 7.74 (s, 1H, H-6), 8.50 (br s, 1H, NH). 10': IR (NaCl) 2958, 1728, 1667, 1442, 1329, 1266, 750 cm⁻¹; ¹H NMR $(CDCl_3, 300 \text{ MHz}) \delta 1.00 \text{ (s, 3H, CH}_3), 1.21 \text{ (s, 3H,}$ CH₃), 0.90–2.04 (m, 7H, sultam), 2.96 (dd, J=13.4, 4.6 Hz, 1H, Ind-CH₂), 3.12 (dd, J=13.4, 9.4 Hz, 1H, Ind-CH₂), 3.43 and 3.52 (2d, J=13.7 Hz, 2H, CH₂SO₂), 3.86 (s, 3H, CH₃O), 4.09 (dd, J=7.5, 4.4 Hz, 1H, $CHNSO_2$), 5.01 (m, 1H, H-2), 5.43 (dd, J=9.6, 5.8 Hz, 1H, H-3), 6.29 (s, 1H, H-3 ind), 6.32 (d, J=9.6 Hz, 1H, H-4), 7.10 (m, 2H, H-5, H-6 ind), 7.32 (d, J=7.3 Hz, 1H, H-7 ind), 7.52 (d, J=7.5 Hz, 1H, H-4 ind), 7.76 (br s, 1H, H-6), 8.30 (br s, 1H, NH); ¹³C NMR (CDCl₃, 75 MHz) δ 19.9 (C-9), 21.0 (C-8), 26.6 (C-5), 32.6 (C-6), 32.9 (Ind-CH₂), 37.8 (C-3), 44.9 (C-4), 47.8 (C-7), 48.0 (C-1), 53.0 (C-2 pyr), 53.4 (C-10), 54.2 (CH₃O), 65.4 (C-2), 101.6 (C-3 ind), 110.7 (C-7 ind), 113.0 (C-5 pyr), 119.4 (C-4 ind), 119.8 (C-5 ind), 120.0 (C-3 pyr), 121.2 (C-6 ind), 121.8 (C-6 pyr), 128.4 (C-3a ind), 133.6 (C-2 pyr), 135.7 (C-6 pyr), 136.1 (C-7a ind), 153.5 (CO_2CH_3) , 166.8 $(CONSO_2)$; m/z 509 (M^+) , 380 (22), 379 (100), 106 (21), 93 (18); HRMS calcd for C₂₇H₃₀N₃O₅S 508.1906, found 508.1882.

3.8. Preparation of (2R)-N-(1-methylnicotinoyl)-bornane-10,2-sultam iodide 11a

A solution of methyl iodide (1.40 mL, 22.4 mmol) in benzene (2 mL) was slowly added to a cooled (0°C) solution of sultam **8** (2.08 g, 6.5 mmol) in acetone (4 mL) and benzene (2 mL). The mixture was stirred for 12 h and the solid was filtered and dried to give **11a** (2.92 g, 97%). **11a**: $[\alpha]_D^{22}$ –179 (*c* 1, EtOH); mp 203°C (acetone); IR (NaCl) 2953, 1680, 1333, 1315, 1201, 1135 cm⁻¹; ¹H NMR (DMSO, 300 MHz) δ 0.96 (s, 3H, CH₃), 1.21 (s, 3H, CH₃), 1.30–2.07 (m, 7H, bornane),

3.76 and 3.99 (2d, J = 14.0 Hz, 2H, CH₂SO₂), 4.14 (dd, J = 7.9, 4.7 Hz, 1H, CHNCO), 4.40 (s, 3H, N-CH₃), 8.27 (dd, J = 8.1, 6.1 Hz, 1H, H-5), 8.75 (d, J = 8.1 Hz, 1H, H-4), 9.15 (d, J = 6.1 Hz, 1H, H-6), 9.34 (s, 1H, H-2); ¹³C NMR (DMSO, 75 MHz) δ 19.7 (C-9), 21.3 (C-8), 26.0 (C-5), 32.1 (C-6), 37.6 (C-3), 44.7 (C-4), 47.7 (C-7), 48.7 (C-1), 48.9 (N-CH₃), 52.5 (C-10), 64.9 (C-2), 128.4 (C-5 pyr), 132.9 (C-3 pyr), 144.8 (C-4 pyr), 145.5 (C-6 pyr), 148.5 (C-2 pyr), 163.2 (CO). Anal. calcd for C₁₇H₂₃IN₂O₃S: C, 44.16; H, 5.01; N, 6.06; S, 6.93; I, 27.45. Found: C, 44.07; H, 5.01; N, 6.08; S, 6.97; I, 27.33.

3.9. Preparation of (2R)-N-(1-benzylnicotinoyl)-bornane-10,2-sultam chloride 11b

Benzyl chloride (3.6 mL, 43.8 mmol) was added to a solution of sultam 8 (2.0 g, 6.2 mmol) in methanol (12 mL). The mixture was heated to 70°C in a sealed tube for 24 h. The solvent was concentrated and the excess of benzyl chloride was removed by vacuum distillation. The residue was washed with Et₂O and dried to give **11b** (2.59 g, 92%). **11b**: $[\alpha]_D^{22}$ –121 (c 1, EtOH); mp 170°C (acetone); IR (NaCl) 1680, 1333, 1306, 1169, 1136 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz) δ 0.99 (s, 3H, CH₃), 1.21 (s, 3H, CH₃), 1.25–2.13 (m, 7H, bornane), 3.51 and 3.56 (2d, J = 14.3 Hz, 2H, CH₂SO₂), 4.17 (br s, 1H, CHNCO), 6.33 (br s, 2H, CH₂C₆H₅), 7.36 (br s, 3H, H-*p*, -*m*), 7.68 (br s, 2H, H-*o*), 8.24 (br s, 1H, H-5), 8.58 (d, J=7.3 Hz, 1H, H-4), 9.43 (br s, 1H, H-6), 10.09 (br s, 1H, H-2); 13 C NMR (CDCl₃, 75 MHz) δ 19.7 (C-9), 21.1 (C-8), 26.2 (C-5), 32.6 (C-6), 37.8 (C-3), 44.7 (C-4), 47.8 (C-7), 48.7 (C-1), 53.1 (C-10), 64.6 (CH₂C₆H₅), 65.5 (C-2), 128.2 (C-5 pyr), 129.3 (C-m), 129.8 (C-p), 129.9 (C-o), 132.3 (C-i), 133.1 (C-3 pyr), 144.6 (C-4 pyr), 144.6 (C-6 pyr), 148.4 (C-2 pyr), 162.6 (CO). Anal. calcd for $C_{23}H_{27}ClN_2O_3S\cdot3/2H_2O$: C, 58.28; H, 6.38; N, 5.90; S, 6.76. Found: C, 58.10; H, 6.30; N, 5.90; S, 6.76.

3.10. Reaction of methyl 1-methyl-2-indoleacetate 1 with (2R)-N-(1-methylnicotinoyl)bornane-10,2-sultam iodide 11a

Operating as described in the general procedure, from ester 1 (264 mg, 1.3 mmol) and pyridinium iodide 11a (600 mg, 1.3 mmol) a residue was obtained. Purification by column chromatography (1:1 EtOAc/hexane) provided four fractions. The first one gave a mixture of the starting ester 1 and (2R)-bornane-10,2-sultam. The second fraction provided *trans*-12a (19 mg, 3%). The third fraction gave a mixture of cis-13a and trans-13a, which were separated by further chromatography (Et₂O; cis-13a: 40 mg; trans-13a: 158 mg; 28% overall yield). The last fraction gave *cis*-12a (50 mg, 7%). *cis*-12a: $[\alpha]_D^{22}$ -385 (c 0.4, CHCl₃); mp 220°C (CH₂Cl₂); IR (NaCl) 2954, 1728, 1592, 1333 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz) δ 0.92 (s, 3H, CH₃), 1.17 (s, 3H, CH₃), 1.17–1.91 (m, 7H, sultam), 1.96 (dt, J = 12.5, 3.5 Hz, 1H, H-12), 2.03 (dt, J=12.5, 2.5 Hz, 1H, H-12), 3.27 (s, 2H, CH₂SO₂), 3.28 (s, 3H, N₂-CH₃), 3.52 (s, 3H, N₇-CH₃), 3.73 (s, 3H, CH₃O), 4.09 (m, 1H, H-5), 4.10 (m, 1H, $CHNSO_2$), 4.20 (d, J = 5.4 Hz, 1H, H-6), 4.53 (br t, 1H,

H-1), 7.10-7.30 (m, 3H, H-8, H-9, H-10), 7.58 (d, J=7.7 Hz, 1H, H-11), 7.62 (s, 1H, H-3); ¹³C NMR $(CDCl_3, 50.3 \text{ MHz}) \delta 19.9 (C-9'), 20.6 (C-8'), 26.9$ (C-5'), 28.4 (C-5), 29.5 (C-12), 30.6 (N₇-CH₃), 32.4 (C-6'), 36.8 (C-3'), 42.8 (N₂CH₃), 44.5 (C-4'), 47.8 (C-7'), 47.9 (C-1'), 48.7 (C-1), 49.1 (C-6), 52.5 (C-10'), 52.9 (CH₃O), 65.4 (C-2'), 101.9 (C-4), 109.3 (C-8), 110.7 (C-11b), 117.4 (C-11), 119.7 (C-10), 121.6 (C-9), 125.4 (C-11a), 134.0 (C-6a), 137.3 (C-7a), 151.9 (C-3), 166.2 (NCO), 171.8 (CO₂). Anal. calcd for $C_{29}H_{35}N_3O_5S\cdot 1/$ 2H₂O: C, 63.70; H, 6.64; N, 7.68; S, 5.86. Found: C, 63.45; H, 6.41; N, 7.37; S, 6.05. trans-12a: $[\alpha]_{D}^{22}$ -153 (c 0.4, CHCl₃); mp 260°C (CH₂Cl₂); IR (NaCl) 3000, 1700, 1595, 1319 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz) δ 0.91 (s, 3H, CH₃), 1.16 (s, 3H, CH₃), 0.90-2.00 (m, 8H, sultam, H-12), 2.38 (dt, J=12.3, 2.6 Hz, 1H, H-12), 3.23 (s, 3H, N₂-CH₃), 3.20 and 3.25 (2d, J=13.7 Hz, 2H, CH₂SO₂), 3.56 (s, 3H, N₇-CH₃), 3.74 (s, 3H, CH₃O), 3.84 (m, 1H, H-5), 3.89 (d, J=1.7 Hz, 1H, H-6), 4.25 (dd, J=7.1, 4.4 Hz, 1H, CHNSO₂), 4.59 (br t, 1H, H-1), 7.10–7.25 (m, 3H, H-8, H-9, H-10), 7.28 (s, 1H, H-3), 7.60 (d, J=7.7 Hz, 1H, H-11); ¹³C NMR (CDCl₃, 75 MHz) & 19.9 (C-9'), 21.8 (C-8'), 25.7 (C-12), 26.8 (C-5'), 29.5 (C-5), 29.6 (N₇-CH₃), 32.9 (C-6'), 37.4 (C-3'), 42.7 (N₂CH₃), 45.0 (C-4'), 45.5 (C-6), 47.6 (C-7'), 47.7 (C-1'), 49.4 (C-1), 52.2 (CH₃O), 52.9 (C-10'), 64.9 (C-2'), 104.2 (C-4), 109.3 (C-8), 109.8 (C-11b), 117.8 (C-11), 119.3 (C-10), 121.2 (C-9), 125.6 (C-11a), 133.9 (C-6a), 137.4 (C-7a), 150.6 (C-3), 165.9 (NCO), 171.8 (CO₂). Anal. calcd for $C_{29}H_{35}N_3O_5S\cdot 3/2H_2O$: C, 62.50; H, 7.06; N, 7.16; S, 5.46. Found: C, 62.51; H, 6.89; N, 6.94; S, 5.68. *cis*-13a: $[\alpha]_{D}^{22}$ +8 (*c* 0.4, CHCl₃); mp 275°C (EtOH); IR (NaCl) 3000, 1738, 1601, 1324 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz) δ 0.93 (s, 3H, CH₃), 1.21 (s, 3H, CH₃), 1.21–1.95 (m, 8H, sultam, H-12), 2.00 (ddd, J=12.3, 3.0, 2.0 Hz, 1H, H-12), 3.07 (s, 3H, N₃-CH₃), 3.23 (s, 2H, CH₂SO₂), 3.48 (s, 3H, N₁₁-CH₃), 3.76 (s, 3H, CH₃O), 4.22 (dd, J=7.4, 4.3 Hz, 1H, CHNSO₂), 4.28 (m, 1H, H-6), 4.28 (br s, 1H, H-1), 4.49 (br t, 1H, H-2), 7.10-7.25 (m, 3H, H-8, H-9, H-10), 7.33 (s, 1H, H-4), 7.70 (d, J = 7.7 Hz, 1H, H-7); ¹³C NMR (CDCl₃, 50.3 MHz) δ 19.9 (C-9'), 20.9 (C-8'), 22.8 (C-6), 26.8 (C-5'), 28.3 (C-12), 30.1 $(N_{11}-CH_3)$, 32.6 (C-6'), 37.3 (C-3'), 44.3 (N₃-CH₃), 44.9 (C-4'), 47.7 (C-1), 47.8 (C-7'), 47.9 (C-1'), 52.6 (C-10'), 52.7 (CH₃O), 55.8 (C-2), 64.9 (C-2'), 108.4 (C-10), 108.4 (C-6a), 118.0 (C-5), 119.1 (C-7), 119.7 (C-8), 121.4 (C-9), 124.5 (C-6a), 128.0 (C-11a), 137.0 (C-10a), 149.9 (C-4), 166.5 (NCO), 172.1 (CO₂). Anal. calcd for C₂₉H₃₅N₃O₅: C, 64.78; H, 6.56; N, 7.81; S, 5.96. Found: C, 64.71; H, 6.58; N, 7.72; S, 6.01. trans-13a: $[\alpha]_{D}^{22}$ +6 (c 0.4, CHCl₃), $[\alpha]_{D}^{22}$ +7 (c 0.2, EtOH); mp 250°C (acetone); IR (NaCl) 3000, 1700, 1598, 1322 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz) δ 0.92 (s, 3H, CH₃), 1.20 (s, 3H, CH₃), 1.26–1.92 (m, 7H, sultam), 1.80 (m, 1H, H-12), 2.30 (ddd, J= 12.5, 3.4, 1.6 Hz, 1H, H-12), 3.17 (s, 3H, N₃-CH₃), 3.22 (s, 2H, CH₂SO₂), 3.53 (s, 3H, N₁₁-CH₃), 3.74 (s, 3H, $CH_{3}O$, 3.93 (d, J=1.4 Hz, 1H, H-1), 4.00 (m, 1H, H-6), 4.25 (dd, J=7.1, 3.6 Hz, 1H, CHNSO₂), 4.53 (br t, 1H, H-2), 7.01–7.17 (m, 3H, H-8, H-9, H-10), 7.37 (s, 1H, H-4), 7.64 (d, J=7.7 Hz, 1H, H-7); ¹³C NMR (CDCl₃, 50.3 MHz) & 19.8 (C-9'), 20.8 (C-8'), 22.8 (C-6), 25.7 (C-12), 26.7 (C-5'), 29.7 (N₁₁-CH₃), 32.5 (C-6'), 37.2 (C-3'), 42.0 (N₃-CH₃), 43.8 (C-1), 44.9 (C-4'), 47.5 (C-7'), 47.8 (C-1'), 52.6 (C-10'), 52.6 (CH₃O), 56.7 (C-2), 65.1 (C-2'), 107.5 (C-6a), 108.2 (C-10), 117.0 (C-5), 118.7 (C-7), 120.0 (C-8), 121.4 (C-9), 125.0 (C-6b), 126.8 (C-11a), 137.3 (C-10a), 149.9 (C-4), 165.9 (NCO), 170.8 (CO₂). Anal. calcd for C₂₉H₃₅N₃O₅S: C, 64.78; H, 6.56; N, 7.81; S, 5.96. Found: C, 64.64; H, 6.42; N, 7.68; S, 5.83. 14: IR (NaCl) 3000, 1624, 1584, 1322, 1245 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz, most relevant signals) δ 0.99 (s, 3H, CH₃), 1.27 (s, 3H, CH₃), 0.90–1.90 (m, 7H, sultam), 2.95 and 3.05 (2d, J = 5.2 Hz, 3H, NH-CH₃), 3.18 and 3.36 (2d, J=13.7 Hz) and 3.34 and 3.40 (2d, J=13.7 Hz, 2H, CH₂SO₂), 3.55 (s, 3H, CH₃O), 3.75 (s, 3H, N-CH₃ ind), 4.10 (m, 1H, CHNSO₂), 4.75 (br s, 1H, NH-CH₃), 6.05 (dd, J = 15.0, 11.0 Hz, 1H, H-4), 6.45 (s, 1H, H-3 ind), 7.10-7.40 (m, 5H, Ar ind, H-5, H-7), 7.60 (d, 1H, H-4 ind), 7.75 (d, J=11.0 Hz, 1H, H-3), 9.40 (br s, 1H, NH); ¹³C NMR (CDCl₃, 50.3 MHz) δ 19.8 (C-9'), 20.8 (C-8'), 26.7 (C-5'), 30.3 (N-CH₃), 32.6 (C-6'), 35.8 (NH-CH₃), 37.1 (C-3'), 44.7 (C-4'), 47.7 (C-7'), 48.0 (C-1'), 51.8 (CH₃O), 52.5 (C-10'), 64.8 (C-2'), 100.0 (C-6), 103.1 (C-3 ind), 109.2 (C-7 ind), 112.6 (C-4), 116.1 (C-2), 119.0 (C-4 ind), 120.4 (C-5 ind), 121.0 (C-6 ind), 127.7 (C-3a ind), 135.1 (C-2 ind), 137.3 (C-7a ind), 142.0 (C-5), 148.4 (C-3), 155.6 (C-7), 167.7 (NCO), 170.8 (CO₂).

3.11. Reaction of methyl 1-methyl-2-indoleacetate 1 with (2R)-N-(1-benzylnicotinoyl)bornane-10,2-sultam chloride 11b

Operating as described above, from ester 1 (273 mg, 1.34 mmol) and pyridinium chloride 11b (600 mg, 1.34 mmol) a residue was obtained. Purification by column chromatography (8:2 Et₂O/hexane) gave as first fraction consisting of a mixture of ester 1 and (2R)-bornane-10,2-sultam. The second fraction gave a mixture of trans-12b, trans-13b and trans-13'b (160 mg). Further purifications by column chromatography (4:6 EtOAc/hexane; 9.7:0.3 $CH_2Cl_2/EtOAc$; 9:1 $CH_2Cl_2/$ EtOAc) provided analytical samples. The third fraction gave cis-12b (60 mg). The overall yield for the four isomers was 27%. *cis*-12b: $[\alpha]_{D}^{22}$ -387 (*c* 0.4, CHCl₃); mp 260–262°C (EtOH); IR (NaCl) 1730, 1593, 1324, 1199, 747 cm⁻¹; ¹H NMR (CDCl₃, 200 MHz) δ 0.90 (s, 3H, CH₃), 1.05 (s, 3H, CH₃), 1.12–1.95 (m, 8H, 7H sultam, H-12), 1.99 (dm, J=12.4 Hz, 1H, H-12), 3.25 (s, 2H, CH₂SO₂), 3.52 (s, 3H, N-CH₃), 3.76 (s, 3H, CH₃O), 4.10 (m, 1H, CHNSO₂), 4.11 (m, 1H, H-5), 4.20 (d, J = 5.0 Hz, 1H, H-6), 4.54 and 4.74 (2d, J = 15.2 Hz, 2H, CH₂C₆H₅), 4.60 (br t, 1H, H-1), 7.10–7.49 (m, 9H, ArH), 7.79 (s, 1H, H-3); ¹³C NMR (CDCl₃, 50.3 MHz) δ 19.9 (C-9'), 20.4 (C-8'), 26.8 (C-5'), 28.6 (C-5), 29.7 (C-12), 30.6 (N-CH₃), 32.3 (C-6'), 36.7 (C-3'), 44.4 (C-4'), 47.0 (C-6), 47.7 (C-7'), 47.9 (C-1'), 48.5 (C-1), 52.4 (C-10'), 52.9 (CH₃O), 59.0 (CH₂SO₂), 65.3 (C-2'), 102.2 (C-4), 109.2 (C-8), 110.7 (C-11b), 117.3 (C-11), 119.6 (C-10), 121.5 (C-9), 125.2 (C-11a), 127.7 (C-m), 128.0 (C-p), 129.0 (C-o), 134.1 (C-6a), 136.1 (C-i), 137.3 (C-7a), 151.7 (C-3), 166.6 (NCO), 171.7 (CO₂). Anal. calcd for C₃₅H₃₉N₃O₅S: C, 68.49; H, 6.40; N, 6.84; S, 5.22. Found: C, 68.09; H, 6.62; N, 6.74; S, 5.10.

trans-12b: $[\alpha]_{D}^{22}$ -267 (c 0.4, CHCl₃); mp 249–250°C (EtOH); IR (NaCl) 1733, 1596, 1321, 1196, 751 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz) δ 0.90 (s, 3H, CH₃), 1.05 (s, 3H, CH₃), 1.00–1.95 (m, 8H, 7H, sultam, H-12), 2.38 (dt, J=12.4, 2.2 Hz, 1H, H-12), 3.20 and 3.25 (2d,)J = 13.7 Hz, 2H, CH₂SO₂), 3.57 (s, 3H, N-CH₃), 3.73 (s, 3H, CH₃O), 3.90 (m, 1H, H-5), 3.94 (d, J = 1.6 Hz, 1H, H-6), 4.25 (m, 1H, CHNSO₂), 4.43 and 4.73 (2d, J =15.1 Hz, 2H, CH₂C₆H₅), 4.66 (br t, 1H, H-1), 7.08–7.48 (m, 8H, ArH), 7.36 (s, 1H, H-3), 7.52 (d, J=7.5 Hz, 1H, H-11); ¹³C NMR (CDCl₃, 75 MHz) δ 19.7 (C-9'), 20.8 (C-8'), 25.9 (C-12), 26.7 (C-6'), 29.5 (C-5), 29.8 (N-CH₃), 32.7 (C-5'), 37.2 (C-3'), 44.9 (C-4'), 45.4 (C-6), 47.4 (C-1), 47.5 (C-7'), 47.6 (C-1'), 52.1 (CH₃O), 52.8 (C-10'), 58.9 (CH₂C₆H₅), 64.8 (C-2'), 104.6 (C-4), 109.3 (C-8), 109.8 (C-11b), 117.7 (C-11), 119.2 (C-10), 121.1 (C-9), 125.4 (C-11a), 127.8 (C-m), 128.1 (C-p), 128.8 (C-o), 134.0 (C-6a), 136.1 (C-i), 137.3 (C-7a), 150.2 (C-3), 167.2 (NCO), 171.6 (CO₂). Anal. calcd for C₃₅H₃₉N₃O₅S: C, 68.49; H, 6.40; N, 6.84; S, 5.22. Found: C, 68.30; H, 6.44; N, 6.81; S, 5.04. trans-13b: IR (NaCl) 1736, 1598, 1323, 1196, 749 cm⁻¹; ¹H NMR $(CDCl_3, 300 \text{ MHz}) \delta 0.92 \text{ (s, 3H, CH}_3), 1.15 \text{ (s, 3H,}$ CH₃), 1.24–1.96 (m, 7H, sultam), 1.77 (ddd, J=12.5, 4.2, 2.8 Hz, 1H, H-12), 2.28 (ddd, J=12.5, 3.2, 1.5 Hz, 1H, H-12), 3.23 (s, 2H, CH₂SO₂), 3.40 (s, 3H, N-CH₃), 3.68 (s, 3H, CH₃O), 3.73 (d, J = 1.6 Hz, 1H, H-1), 4.16 (m, 1H, H-6), 4.25 (m, 1H, CHNSO₂), 4.48 and 4.57 $(2d, J=15.4 \text{ Hz}, 2H, CH_2C_6H_5), 4.56 (br s, 1H, H-2),$ 7.03-7.38 (m, 8H, ArH), 7.56 (s, 1H, H-4), 7.65 (d, J=7.7 Hz, 1H, H-7); ¹³C NMR (CDCl₃, 50.3 MHz) δ 19.9 (C-9'), 20.9 (C-8'), 23.2 (C-6), 26.1 (C-12), 26.8 (C-5'), 29.6 (N-CH₃), 32.6 (C-6'), 37.3 (C-3'), 44.7 (C-1), 45.0 (C-4'), 47.7 (C-7'), 47.9 (C-1'), 52.6 (CH₃O), 52.7 (C-10'), 55.1 (C-2), 59.4 (CH₂C₆H₅), 65.1 (C-2'), 108.2 (C-6a), 108.3 (C-10), 116.9 (C-5), 118.9 (C-7), 120.3 (C-8), 121.5 (C-9), 125.1 (C-6b), 127.0 (C-11a), 127.5 (C-m), 128.2 (C-p), 129.0 (C-o), 136.7 (C-i), 137.4 (C-10a), 149.5 (C-4), 166.5 (NCO), 170.8 (CO₂). trans-**13'b**: IR (NaCl) 1700, 1595, 1325, 1196, 747 cm⁻¹; ¹H NMR (CDCl₃, 200 MHz) δ 0.89 (s, 3H, CH₃), 1.03 (s, 3H, CH₃), 1.10–1.92 (m, 8H, 7H sultam, H-12), 2.20 $(dm, J=12.4 Hz, 1H, H-12), 3.37 (s, 2H, CH_2SO_2), 3.50$ $(s, 3H, N-CH_3), 3.68 (s, 3H, CH_3O), 3.92 (d, J=1.4 Hz,$ 1H, H-1), 4.04 (m, 1H, H-6), 4.26 (dd, J=7.8, 4.4 Hz, 1H, CHNSO₂), 4.30 (br t, 1H, H-2), 4.52 (s, 2H, CH₂C₆H₅), 7.09–7.39 (m, 8H, ArH), 7.51 (s, 1H, H-4), 8.28 (d, J = 6.6 Hz, 1H, H-7); ¹³C NMR (CDCl₃, 50.3 MHz) δ 19.8 (C-9'), 20.8 (C-8'), 23.8 (C-6), 26.2 (C-12), 26.7 (C-5'), 29.6 (N-CH₃), 32.7 (C-6'), 37.0 (C-3'), 44.5 (C-1), 44.8 (C-4'), 47.5 (C-7'), 47.8 (C-1'), 52.6 (CH₃O), 52.7 (C-10'), 53.3 (C-2), 58.5 (CH₂C₆H₅), 65.1 (C-2'), 107.6 (C-6a), 108.2 (C-10), 116.8 (C-5), 119.1 (C-7), 121.3 (C-8), 121.6 (C-9), 125.5 (C-6b), 127.7 (C-11a), 127.9 (C-m), 128.2 (C-p), 129.0 (C-o), 136.0 (C-i), 137.3 (C-10a), 150.8 (C-4), 165.3 (NCO), 170.4 (CO₂).

Acknowledgements

This work was supported by the DGICYT, Spain (projects PB94-0214 and BQU2000-0651). Thanks are

also due to the DURSI, Generalitat de Catalunya, for Grant 2001SGR-0084 and a fellowship to M.-D.C., the SCT of the University of Barcelona for recording the NMR and mass spectra, and Jordi Molins for technical assistance.

References

- For reviews, see: (a) Sapi, J.; Massiot, G. In Monoterpenoid Indole Alkaloids; Saxton, J. E., Ed. In The Chemistry of Heterocyclic Compounds; Taylor, E. C., Ed.; Wiley: Chichester, 1994; Supplement to Vol. 25, Part 4, Chapter 7; (b) Bosch, J.; Bonjoch, J.; Amat, M. In The Alkaloids; Cordell, G. A., Ed.; Academic Press: New York, 1996; Vol. 48, pp. 75–189; (c) Bonjoch, J.; Solé, D. Chem. Rev. 2000, 100, 3455–3482.
- Biogenetic numbering: Le Men, J.; Taylor, W. I. Experientia 1965, 21, 508–510.
- For precedents of this key cyclization (in the racemic series), see: (a) Amat, M.; Linares, A.; Bosch, J. J. Org. Chem. 1990, 55, 6299–6312; (b) Gràcia, J.; Casamitjana, N.; Bonjoch, J.; Bosch, J. J. Org. Chem. 1994, 59, 3939– 3951.
- For a recent review on the chemistry of dihydropyridines, see: Lavilla, R. J. Chem. Soc., Perkin Trans. 1 2002, 1141–1156.
- 5. For the generation of enantiopure 1,4-dihydropyridines by addition of organometallic reagents to pyridines and pyridinium salts bearing a chiral auxiliary at the 3-position of the ring, see: (a) Meyers, A. I.; Natale, N. R.; Wettlaufer, D. G.; Rafii, S.; Clardy, J. Tetrahedron Lett. 1981, 22, 5123-5126; (b) Meyers, A. I.; Oppenlaender, T. J. Chem. Soc., Chem. Commun. 1986, 920-921; (c) Meyers, A. I.; Oppenlaender, T. J. Am. Chem. Soc. 1986, 108, 1989-1986; (d) Mangeney, P.; Gosmini, R.; Raussou, S.; Commerçon, M.; Alexakis, A. J. Org. Chem. 1994, 59, 1877-1888; (e) Raussou, S.; Gosmini, R.; Mangeney, P.; Alexakis, A.; Commerçon, M. Tetrahedron Lett. 1994, 35, 5433-5436; (f) Yamada, S.; Misono, T.; Ichikawa, M.; Morita, C. Tetrahedron 2001, 57, 8939-8949; (g) Yamada, S.; Morita, C. J. Am. Chem. Soc. 2002, 124, 8184–8185; (h) Yamada, S.; Saitoh, M.; Misono, T. Tetrahedron Lett. 2002, 43, 5853-5857.
- For the generation of enantiopure tetracyclic ABDE substructures of *Strychnos* alkaloids using this methodology from a chiral non-racemic 3-(oxazolinyl)pyridine, see: Amat, M.; Coll, M.-D.; Bosch, J. *Tetrahedron* 1995, *39*, 10759–10770.
- For a review, see: (a) Bosch, J.; Bennasar, M.-L. Synlett 1995, 587–596. For more recent work, see: (b) Bennasar, M.-L.; Jiménez, J.-M.; Vidal, B.; Sufi, B. A.; Bosch, J. J. Org. Chem. 1999, 64, 9605–9612; (c) Bennasar, M.-L.; Vidal, B.; Bosch, J. J. Org. Chem. 1997, 62, 3597–3609; (d) Bennasar, M.-L.; Vidal, B.; Kumar, R.; Lázaro, A.; Bosch, J. Eur. J. Org. Chem. 2000, 3919–3925.
- (a) Bennasar, M.-L.; Zulaica, E.; Alonso, Y.; Bosch. J. *Tetrahedron: Asymmetry* 2003, *14*, 469–479. For the stereoselective generation of 1,4-dihydropyridines by addition of chiral non-racemic nucleophiles to pyridinium salts in the synthesis of alkaloids, see: (b) Amann, R.;

Spitzner, D. Angew. Chem., Int. Ed. 1991, 30, 1320–1321;
(c) Amann, R.; Arnold, K.; Spitzner, D.; Majer, Z.;
Snatzke, G. Liebigs Ann. 1996, 349–355;
(d) Bennasar, M.-L.; Zulaica, E.; Alonso, Y.; Vidal, B.; Vázquez, J. T.;
Bosch, J. Tetrahedron: Asymmetry 2002, 13, 95–106.

- 9. (a) Furukawa, N.; Shibutani, T.; Matsumura, K.; Fujihara, H.; Oae, S. *Tetrahedron Lett.* **1986**, *27*, 3899–3902;
 (b) Imanishi, T.; Obika, S.; Nishiyama, T.; Nishimoto, M.; Hamano, Y.; Miyashita, K.; Iwata, C. *Chem. Pharm. Bull.* **1996**, *44*, 267–272.
- Bennasar, M.-L.; Álvarez, M.; Lavilla, R.; Zulaica, E.; Bosch, J. J. Org. Chem. 1990, 55, 1156–1168.
- 11. The ratio of H_5 - H_6 *cis/trans* isomers shifted to 4:1 for *rac*-**3** and 7:3 for *rac*-**3**' when the temperature during the nucleophilic addition was allowed to rise to -10° C.
- 12. For previous use of this criteria, see Ref. 10.
- For reviews, see: (a) Davies, S. G. Pure Appl. Chem. 1988, 60, 13–20; (b) Davies, S. G. Aldrichimica Acta 1990, 23, 31–37.
- Beckett, R. P.; Burgess, V. A.; Davies, S. G.; Whittaker, M. *Tetrahedron Lett.* 1993, *34*, 3617–3620.
- Davies, S. G.; Edwards, A. J.; Skerlj, R. T.; Sutton, K. H.; Whittaker, M. J. Chem. Soc., Perkin Trans. 1 1991, 1027–1034.
- (a) Oppolzer, W.; Chapuis, C.; Bernardinelli, G. Helv. Chim. Acta 1984, 67, 1397–1401; (b) Spivey, A. C. In Encyclopedia of Reagents for Organic Synthesis; Paquette, L. A., Ed.; Wiley: Chichester, 1995; Vol. 2, pp. 975–981.
- This kind of ring opening has previously been observed: Wenkert, W.; Angell, C.; Drexler, J.; Moeller, P. D. R.; Pyrek, J. S.; Shi, Y.-J.; Sultana, M.; Vankar, Y. D. J. Org. Chem. 1986, 51, 2995–3000 see also Ref. 10.
- 18. The ratios of isolated products cis-12a/trans-12a and cis-13a/trans-13a were 7:3 and 1:4, respectively (cis/trans refers to the relative H_5-H_6 stereochemistry in 12a and H_1-H_2 in 13a). For 13a this ratio shifted to 1:1 when the temperature during the nucleophilic addition was allowed to rise to +10°C.
- 19. The experiment was done on an Enraf-Nonius CAD4 diffractometer using graphite monochromated Mo Ka radiation. The structure was solved by direct methods using SHELXS97 [Sheldrick, G. M. 1997, SHELX97. Programs for Crystal Structure Analysis (Release 97-2), University of Göttingen, Germany] after applying Lorentz, polarization, and absorption (semiempirical PSI scan method) corrections. Full-matrix least squares refinement (SHELXL-97) with anisotropic thermal parameters for non-H atoms and riding thermal parameters for H-atoms (positioned at calculated positions) converged to a R factor of 0.0449 (calculated for the reflections with $I > 2\sigma(I)$). Crystal data: C₃₅H₃₉N₃O₅S, hexagonal, space group $P3_1$, a=18.168(3), b=18.168(3), c=8.318(2) Å, $V = 2377.7 \text{ Å}^3$, Z = 3, μ (Mo K α) = 0.149 mm⁻¹, $D_{\text{calcd}} =$ 1.286 g/cm³. Data collection was up to a resolution of $2\theta = 50.0^{\circ}$ producing 7683 reflections. Largest peak and hole at the final difference Fourier synthesis were 0.156 and -0.198 e Å⁻³. Calculations were done using the WinGX package (Farrugia, L. J. J. Appl. Cryst. 1999, 32, 837-838).